mRNA LECTURE SERIES 2:

Based on the demand and success of the first lecture series, mRNA Victoria and BioMelbourne Network, are pleased to host a second series of four lectures beginning in November 2023 for the Victorian RNA community.

These lectures present an opportunity for global leading specialists in the RNA field to share their knowledge with the local RNA community. The accompanying networking sessions are an opportunity to foster connections between researchers, industry and government to build a connected and collaborative ecosystem in Victoria.

Series Overview:

Lecture One: The RNA Platform: The Breadth of Possibility Beyond mRNA | Friday 10 November 2023, 8:00am – 11:00am

Lecture Two: mRNA Clinical Trials: Enhancing Research-Clinician Collaboration to Accelerate Patient Outcomes | Tuesday 20 February 2024, 8:00am – 11:00am

Lecture Three: Details tbc | Thursday 11 April 2024, 8:00am – 11:00am

Lecture Four: Details tbc | Tuesday 28 May 2024, 8:00am – 11:00am

Registration:

BioMelbourne Network Members: $0
BioMelbourne Network Non Members: $85

Who should attend?

  • Professionals seeking to improve knowledge and foster connections in the RNA industry
  • mRNA technology professionals developing products for the local or global market 
  • Executives, scientists, researchers, manufacturers and industry service providers engaged in the RNA technology landscape.

This lecture series is delivered in partnership with mRNA Victoria and the State Government of Victoria

Upcoming Lectures

Series 2: Lecture Three: 


Coming soon...

Location
Treasury Theatre,
Lower Plaza,
1 Macarthur Street,
East Melbourne 3000
Date & Time
Thursday 11 April 2024
8am to 11am
Past Lectures 
Explore Series One and Series Two Lectures Below

Series 2: Lecture Two: 

mRNA Clinical Trials: Enhancing Research-Clinician Collaboration to Accelerate Patient Outcomes


The agility of the mRNA platform provides new opportunities for innovation in the delivery of clinical trials that could accelerate and improve the drug development process. This lecture will explore the opportunities of mRNA clinical trials for researchers, clinicians and the broader sector and speakers will share their experiences from conducting their own mRNA clinical trials.

The intended audience is those that have an interest in developing an mRNA candidate to take to clinical trials, researchers who have non-mRNA candidates who are exploring an accelerated option using the mRNA platform, and industry professionals, students and academics who are interested to learn more about the workforce opportunities to support the mRNA industry in the future.

Guest speakers:
Professor Riccardo Dolcetti, Head, Clinical and Translational Immunotherapy, Peter MacCallum Cancer Centre
Dr Iris Depaz, Country Medical Lead & Head of Medical Vaccines, Sanofi ANZ
Associate Professor Jennifer Short, Director, Monash Centre for Advanced mRNA Medicines Manufacturing and Workforce Training

Facilitated by:
Dr Kylie Quinn, Vice-Chancellor’s Research Fellow, School of Health and Biomedical Sciences, RMIT University
Location
Treasury Theatre,
Lower Plaza,
1 Macarthur Street,
East Melbourne 3000
Date & Time
Tuesday 20 February 2024
8am to 11am
Speakers
Professor Riccardo Dolcetti
Head, Clinical and Translational Immunotherapy, Peter MacCallum Cancer Centre
Dr Iris Depaz
Country Medical Lead & Head of Medical Vaccines, Sanofi ANZ
Associate Professor Jennifer Short
Director, Monash Centre for Advanced mRNA Medicines Manufacturing and Workforce Training
Dr Kylie Quinn
Vice-Chancellor’s Research Fellow, School of Health and Biomedical Sciences, RMIT University

Series One - Lecture One 

Introduction to the Intellectual Property Landscape, the Product Development Pathway and Leveraging Existing Capabilities in the Development of New RNA Therapeutics


Guest Speakers:
Rachel Sciascia, Legal Practitioner Director, Deloitte Legal
Dr Patricia Vietheer, Director, R&D Strategy & Planning, Biointelect
Dr James Patterson, Executive Director Manufacturing, mRNA Victoria

Opening Remarks:
Michael Kapel, Chief Executive Officer, mRNA Victoria
Dr James Patterson, Executive Director Manufacturing, mRNA Victoria
Location
Treasury Theatre, Lower Plaza, 1 Macarthur St, Melbourne VIC 3000
Date & Time
Tuesday 7 February 2023
5pm to 7pm
Speakers
Michael Kapel
Chief Executive Officer
mRNA Victoria
Dr James Patterson
Executive Director Manufacturing
mRNA Victoria
Rachel Sciascia
Legal Practitioner Director
Deloitte Legal
Dr Patricia Vietheer
Director, R&D Strategy & Planning
Biointelect

Series One - Lecture Two

Fireside Chat with Professor Robert Langer, Co-Founder of Moderna, Institute Professor at MIT

Professor Robert Langer is an American chemical engineer and Co-Founder of Moderna. He is one of twelve Institute Professors at the Massachusetts Institute of Technology, holds over 1,400 granted or pending patents and is one of the most highly cited researchers in the world.

During this fireside chat, Professor Langer dialed in live from Boston and spoke about his career, shared lessons he learnt along the way, and participated in Q&A facilitated by Professor Christopher Porter, Director of the Monash Institute of Pharmaceutical Sciences.

Guest speaker (live streamed from Boston):
Professor Robert Langer, Co-Founder, Moderna & Institute Professor, Massachusetts Institute of Technology (MIT)

Facilitator:
Professor Chris Porter, Director, Monash Institute of Pharmaceutical Sciences, Monash University
Location
Gippsland Room, Investment Centre Victoria, Level 46, 55 Collins St, Melbourne
Date & Time
Tuesday 21 March 2023
9am to 10.15am
Speakers
Professor Robert Langer (USA)
Co-Founder, Moderna
Institute Professor, Massachusetts Institute of Technology (MIT)
Professor Chris Porter
Director, Monash Institute of Pharmaceutical Sciences
Monash University

Series One - Lecture Three

Exploring the Clinical Trials Landscape 


The third lecture in the mRNA Victoria and BioMelbourne Network lecture series is focused on clinical trials and associated considerations. The session will be chaired by Michelle Gallagher (CEO, Opyl) and will include presentations from three speakers followed by a Q&A panel discussion. The intended audience is those that have an interest in the progression of RNA based candidates from preclinical development to clinical trials and the steps taken in order to ensure the appropriate decisions are made for study design and execution. The emphasis will be on specific considerations for progressing RNA based candidates to clinic and where the field can progress in the future.

We are fortunate to have three speakers with expertise across a range of facets associated with clinical trial screening, planning and delivery.

Guest speaker (live streamed from Boston):
Dr Jason Lickliter, Chief Medical Officer, Nucleus Network
Professor Elizabeth Hartland, Director and CEO, Hudson Institute of Medical Research
Dr Paul Burton, Chief Medical Officer, Moderna (USA)

Facilitator:
Michelle Gallaher, CEO, Opyl
Location
International Chamber House, Theatrette, Level 5, 121 Exhibition Street, Melbourne 3000
Date & Time
Tuesday 2 May 2023
4.30pm to 6pm
Speakers
Dr Paul Burton (USA)
Chief Medical Officer
Moderna
Professor Elizabeth Hartland
Director and CEO
Hudson Institute of Medical Research
Dr Jason Lickliter
Chief Medical Officer
Nucleus Network
Michelle Gallaher
Chief Executive Officer
Opyl Ltd

Series One - Lecture Four

Enabling RNA Technology

The fourth lecture in the mRNA Victoria and BioMelbourne Network lecture series focuses on enabling technologies and their application for the development of RNA based products. The session will be chaired by Professor Michelle McIntosh (Director, Medicine Manufacturing Innovation Centre) and will include presentations from three speakers followed by a Q&A panel discussion.

The intended audience is those that have an interest in the development of RNA based candidates with an emphasis on the CMC (chemistry, manufacturing and control) considerations for progressing an asset through the clinic and eventual commercial production.

Guest speakers:
Dr Natalie Curach, Senior Director Business Development, Gingko Bioworks
Professor Frank Caruso, Melbourne Laureate Professor and NHMRC Leadership Fellow, The University of Melbourne
Dr Craig Sheehan, Senior Scientist, IDT Australia

Facilitator:
Professor Michelle McIntosh, Director, Medicine Manufacturing Innovation Centre, Monash University
Location
International Chamber House, Theatrette, Level 5, 121 Exhibition Street, Melbourne 3000
Date & Time
Tuesday 6 June 2023
4.30pm to 6pm
Speakers
Professor Frank Caruso
Melbourne Laureate Professor | NHMRC Leadership Fellow
The University of Melbourne
Dr Natalie Curach
Senior Director Business Development
Gingko Bioworks
Dr Craig Sheehan
Senior Scientist
IDT Australia
Professor Michelle McIntosh
Director, Medicines Manufacturing Innovation Centre (MMIC)
Monash University

Series Two - Lecture One


The RNA Platform: The Breadth of Possibility Beyond mRNA

The first lecture in Series 2 focused on the RNA platform and its different modalities beyond mRNA.

RNA is an emerging global modality that promises treatments for previously ‘undruggable’ diseases. While the COVID pandemic proved the efficacy of mRNA vaccines, RNA as a platform technology has broader implications across multiple modalities such as mRNA, anti-sense oligonucleotides, short-interfering RNA, self-amplifying RNA, circular RNA and aptamers. It can also be used to encode other functional biological molecules such as monoclonal antibodies and cytokines.

This lecture provided an insight into the breadth of the RNA platform potential and the flexibility it provides to target a range of disease types.

Facilitator:
Associate Professor Misty Jenkins AO, Laboratory Head, Immunology Division, WEHI

Speakers:
Professor Marco Herold, Chief Executive Officer, Olivia Newtown John Cancer Research Institute
Dr Vi Wickramasinghe, Head, RNA Biology and Cancer Laboratory, Peter MacCallum Cancer Centre
Dr Christopher Wraight, CEO and Director, RAGE Biotech

Host: 
Valentina Tan, Research and Industry Development Officer, mRNA Victoria
Location
International Chamber House, Theatrette, Level 5, 121 Exhibition Street, Melbourne 3000
Date & Time
Tuesday 10 November 2023
8am to 10.30pm
Speakers
Associate Professor Misty Jenkins AO
 Laboratory Head, Immunology Division, WEHI
Professor Marco Herold
Chief Executive Officer, Olivia Newtown John Cancer Research Institute
Dr Vi Wickramasinghe
RNA Biology and Cancer Laboratory, Peter MacCallum Cancer Centre
Dr Christopher Wraight
CEO and Director, RAGE Biotech
Partners
BioMelbourne Network

Web: biomelbourne.org
Email: [email protected]
LinkedIn: linkedin.com/company/biomelbourne-network/
Twitter: twitter.com/biomelb

BioMelbourne Network is the peak body in the Victorian healthtech industry, driving engagement and growth through local and international networks. Since 2001, we are actively fostering and growing an innovative, globally competitive sector and transforming our Network as well as the broader Victorian ecosystem.

Our members are diverse and experts in their respective fields, from early-career researchers to company executives and experienced directors, and start-ups through to large multinational corporations. We represent universities, researchers, manufacturers, government departments and the services sector, which includes commercialisation, product design and development, intellectual property, investment and legal sectors.

We are committed to maximising our value to the ecosystem through the delivery of our three-year strategic plan.
mRNA Victoria

Web: djsir.vic.gov.au/medical-research/initiatives/mrna-victoria
Email: [email protected] 
LinkedIn: linkedin.com/company/mrna-victoria/

mRNA Victoria is responsible for leading the Victorian Government’s commitment to establish a world-class mRNA and RNA industry in Victoria, by supporting supply chain, research and development for pre and clinical research, commercialisation and manufacturing investments.

Its role is to identify key capabilities, gaps, opportunities and lead the Victorian Government’s engagement, investment and partnerships with domestic and international companies, researchers and stakeholders to build RNA capability.
State Government of Victoria

Web: djsir.vic.gov.au
Email: [email protected]
LinkedIn: linkedin.com/company/department-of-jobs-skills-industry-and-regions/
Twitter: https://twitter.com/VicGov_DJSIR 

Victoria is home to world-class health technology companies and is a preferred location for many international organisations including CSL, Moderna, Illumina, Gingko Bioworks and Johnson & Johnson. There are many reasons international organisations choose Victoria for commercial product development – its cost-competitive environment for basic discovery, clinical and commercial research, strong collaborative networks and a supportive government.

Victoria’s key research and development capabilities include:
· Infectious disease and diagnostics
· Digital health and patient monitoring
· Cancer
· Cell therapies and regenerative medicine
· Neuroscience

Victoria’s health technologies expertise is supported by its experienced talent pool, favourable regulatory and research and development environment, and world leading infrastructure all backed by the Victorian Government’s investment into the sector.

The Victorian Government has charted a bold course to continue building a globally competitive research and innovation ecosystem. Its global network of 23 international business offices is working with companies worldwide to develop novel health technologies and services.

We would welcome the opportunity to talk with you further to discuss how we can provide you with our insights and offer you the full range of capabilities and talent in Victoria.

Processing Registration...